Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704 Journal Article

Local Library Link: Find It @ Loyola

Authors: Puvvada, S. D.; Stiff, P. J.; LeBlanc, M; Cook, J. R.; Couban, S; Leonard, J. P.; Kahl, B.; Marcellus, D.; Shea, T. C.; Winter, J. N.; Li, H; Rimsza, L. M.; Friedberg, J. W.; Smith, S. M.
Article Title: Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704
Abstract: Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/-R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13.6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.
Journal Title: British journal of haematology
ISSN: 1365-2141; 0007-1048
Publisher: Wiley Periodicals, Inc  
Date Published: 2016
Language: ENG
DOI/URL:

10.1111/bjh.14100
Notes: LR: 20160414; CI: (c) 2016; JID: 0372544; OTO: NOTNLM; 2015/10/06 [received]; 2016/01/22 [accepted]; aheadofprint